Quell Therapeutics’ Post

Ready to talk about scale up for iPSCs to hundred of billions of cells per batch?

Allo. versus auto.? All wrong... My colleague Hannah Glazier and I were able to sit down with Peter Olagunju and discuss all things cell therapy covering the past, present, and what the future might hold. Full writeup here: https://lnkd.in/g_5uADyy Some key takeaways from what was an insightful discussion: Allo vs. auto. is all wrong: There will be room for both across different indication types and settings. Of course, auto. has a bit of a head start and with allo. its not so much the engineering challenge that auto faces but one of biology. Underinvestment in QC/QA: The field has focused on the process to optimize every bit of it but at the expense of next-gen. assays and analytical methods. Imagine if you could, in real time, pick out those CAR-Ts that actually recognized and killed cancer, for example? That right there would greatly shorten your expansion time, TAT, and improve potency and potentially reduce side effects. Making a global impact: We have to remember that patients outside of the U.S. and EU can also benefit from these breakthrough medicines and think about how we can effectively deliver them to geographies outside these territories where the burden of certain diseases is astronomically high. Altogether, we're grateful to Peter for sitting down with us and sharing his collective wisdom in cell therapy. #pharma #celltherapy #drugdiscovery

#iPSCs, with their promise and complexity, are shaping the future of advanced cell therapies. They present unique challenges and opportunities in gene-editing, including the integration of CRISPR technology for iPSC-derived allogeneic cell therapies. Gain valuable insights into the challenges of employing gene-editing techniques for iPSC-derived therapies from Suzanne Snellenberg, Cellistic's VP of Cell Line Development. Read the full article at the link below and feel to reach out for more information! 💡🔗 https://hubs.ly/Q02xctr80 #iPSCs #GeneEditing #article

Unlock the Power of Precision in Cell Therapy! How can machine learning elevate UV spectroscopy for more accurate detection in cell therapies? Discover how these cutting-edge tools are reshaping detection limits, refining processes, and enhancing treatment reliability. 💡 Ready to see the future of diagnostics? Dive into the article today and explore the breakthroughs making waves in cell therapy! Read now and redefine what’s possible 👉 https://bit.ly/3Yk5Sr4 #CellTherapyInnovation #MachineLearningInLabs #UVSpectroscopy

T-1 day until DDIF 2024 GBX EVENTS kicks off! Excited to dive into groundbreaking presentations from industry leaders on innovations in digital transformation, GenAI, AI-driven drug discovery, and more. Key topics: - GenAI's role in healthcare and pharma - Transforming cancer and age-related treatments with AI and cell therapy - Patient-first drug discovery - The impact of quantum computing Looking forward to the fireside chats and hearing insights from CxOs about their journey and vision for the future. Exciting times for healthcare ahead!

Gain valuable insights from cell therapy experts on CAR detection advancements, current challenges in CAR-T and CAR-NK therapy development, and exciting innovations on the horizon. Learn more here: https://bit.ly/3X3ELkI

Now that I’ve spent two months getting up to speed on all things Nomic Bio and #nELISA they are finally letting me out in public to speak with customers 😂 In all seriousness, this onboarding has been truly inspiring and solidified my initial hunch that this was a one-of-a-kind place with a legitimate paradigm-shifting technology. The opportunity to introduce researchers to our novel #proteomics solution at events like the #IOSummit here in Philadelphia is extremely motivating. In this industry, it isn’t often that you’re in a postition to solve several long-standing technical challenges while also lowering cost and increasing throughput! And while this is just the beginning, it’s becoming increasingly clear that access to a high-plex, #quantitative #immunoassay panel that enables turnkey flexibility while significantly reducing end-to-end cost is already redefining how, and more importantly how often, proteomics is applied from #drugdiscovery screening campaigns to translational #biomarker studies. I’m looking forward to sharing our advancements with a growing audience of scientists over the coming months and can’t wait to see how we together accelerate and ultimately enable the promise of proteomics.

Deadline tomorrow 🚨 Share your groundbreaking findings on HCT & cell therapy toxicities with global experts at #ToxicitiesConference24. Topics include solid organ malignancies, machine learning, novel approaches to improve outcomes, among others. Learn more & submit by Sept. 8: https://ow.ly/KCFr50T735J

Coming next week, 'Pioneers and visionaries of cell therapy: Episode three'. Hear why the work was personal for Cytiva associates helping to transform healthcare with the Sepax and Sefia cell processing systems. #celltherapy #celltherapydevelopment

Super powerful and completely flexible.